{
    "id": 6676,
    "fullName": "NF2 loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "NF2 loss indicates loss of the NF2 gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4771,
        "geneSymbol": "NF2",
        "terms": [
            "NF2",
            "ACN",
            "BANF",
            "SCH"
        ]
    },
    "variant": "loss",
    "createDate": "05/28/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2248,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib mesylate) inhibited growth and viability of human schwannoma cell lines deficient in NF2 (PMID: 19509233).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3192,
                "name": "neurilemmoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2831,
                    "pubMedId": 19509233,
                    "title": "Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19509233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2245,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Tykerb (lapatinib) resulted in objective volumetric response in 23.5% (4/17) and prolonged stable disease in 17.6% (3/17) of patients with NF2-related vestibular schwannoma (PMID: 22844108).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 12689,
                "name": "acoustic neuroma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2828,
                    "pubMedId": 22844108,
                    "title": "Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22844108"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10443,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torin 1 inhibited proliferation of NF2-deficient primary meningioma cells in culture (PMID: 22426462).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 2247,
                "therapyName": "Torin 1",
                "synonyms": null
            },
            "indication": {
                "id": 3565,
                "name": "meningioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8458,
                    "pubMedId": 22426462,
                    "title": "Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22426462"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3739,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the NSCLC line, PC-9, with NF2 loss had decreased sensitivity to Gilotrif (afatinib) (PMID: 24813888).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4088,
                    "pubMedId": 24813888,
                    "title": "Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24813888"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2237,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited PDGFRB, ERK1/2, and AKT activity and blocked cell proliferation in cultured human primary schwannomas deficient in NF2 (PMID: 18593924).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3192,
                "name": "neurilemmoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2821,
                    "pubMedId": 18593924,
                    "title": "Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18593924"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2242,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) inhibited EGFR and VEGFR activity, induced apoptosis, and reduced tumor growth in human and mouse cell line xenograft models of vestibular schwannoma deficient in NF2 (PMID: 20406973).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 12689,
                "name": "acoustic neuroma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2825,
                    "pubMedId": 20406973,
                    "title": "Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20406973"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2240,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AR-42 reduced activation of AKT and inhibited growth NF2-deficient primary human schwannoma cells and schwannoma cell lines in culture, and induced apoptosis and inhibited tumor growth in cell line xenograft models of NF2-deficient malignant schwannoma (PMID: 21778190).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 987,
                "therapyName": "AR-42",
                "synonyms": null
            },
            "indication": {
                "id": 3192,
                "name": "neurilemmoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2816,
                    "pubMedId": 21778190,
                    "title": "AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21778190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2244,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Tasigna (nilotinib) inhibited PDGFR activation, and resulted in decreased proliferation and increased apoptosis of NF2-deficient vestibular schwannoma cells in culture (PMID: 22745749).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 12689,
                "name": "acoustic neuroma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2827,
                    "pubMedId": 22745749,
                    "title": "Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22745749"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2233,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling and cell proliferation in mouse embryonic fibroblasts deficient in NF2 (PMID: 17548515).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2820,
                    "pubMedId": 17548515,
                    "title": "Contact-dependent inhibition of EGFR signaling by Nf2/Merlin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17548515"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10445,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) inhibited proliferation of NF2-deficient primary meningioma cells in culture (PMID: 22426462).",
            "molecularProfile": {
                "id": 6530,
                "profileName": "NF2 loss"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3565,
                "name": "meningioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8458,
                    "pubMedId": 22426462,
                    "title": "Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22426462"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6530,
            "profileName": "NF2 loss",
            "profileTreatmentApproaches": [
                {
                    "id": 11185,
                    "name": "Bevacizumab",
                    "profileName": "NF2 loss"
                },
                {
                    "id": 11181,
                    "name": "mTOR Inhibitor",
                    "profileName": "NF2 loss"
                },
                {
                    "id": 11182,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "NF2 loss"
                },
                {
                    "id": 11183,
                    "name": "PDGFR Inhibitor (Pan)",
                    "profileName": "NF2 loss"
                },
                {
                    "id": 4995,
                    "name": "AR-42",
                    "profileName": "NF2 loss"
                },
                {
                    "id": 11180,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "NF2 loss"
                },
                {
                    "id": 11184,
                    "name": "VEGFR Inhibitor (Pan)",
                    "profileName": "NF2 loss"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}